Corporate Member Update: Merck

Merck would like to inform you that KEYTRUDA® (pembrolizumab) Injection 100 mg is approved for 42 indications across 18 types of cancer.

• One indication that the FDA has now approved is KEYTRUDA for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.

Click here to read the full press release!